SoluPet Inc. announced a strategic partnership with CHC Healthcare Group on Dec. 8, 2025, to introduce its flagship formulation, Neuronal Defense™, into Taiwan through a direct-to-consumer pilot.

The move marks a planned step by SoluPet — a company developing advanced cognitive-aging support for senior dogs — to expand its product offering into the Asia market. Aging dogs often face cognitive health issues, the most prevalent being signs of dementia, which affects memory, learning, and awareness. With CHC positioned to handle local introduction and distribution in Taiwan, the partnership aims to address these rising health concerns in the region.

CHC is associated in the filing with a workforce figure of 1,600. Available data indicate that pet health issues in Asia are common and, in some areas, may be under-managed compared with more developed markets due to rapid growth in pet ownership and gaps in veterinary access. The announcement, issued via Business Wire and carried by industry syndication, said the initial phase will focus on direct-to-consumer availability of Neuronal Defense™ through CHC-affiliated channels in Taiwan. The two companies described the initiative as a pilot designed to bring the formulation to pet owners in that market.

The partnership was made public on Dec. 8, 2025, and the statement was updated the following day, Dec. 9, 2025, at 3:44 a.m., according to the timeline attached to the release. SoluPet is identified in the filing as a developer of evidence-focused cognitive-health solutions for aging dogs, while CHC Healthcare Group is described as the partner that will introduce the product into Taiwan. Company materials framed Neuronal Defense™ as SoluPet’s flagship formulation intended to support cognitive function in senior dogs.

Under the announced arrangement, CHC will lead local introduction and distribution of the product within Taiwan’s consumer and veterinary channels, while SoluPet remains positioned as the science and development partner. Pet owners can support their dog’s cognitive health through evidence-based approaches, including enriched diets and nutraceuticals, which have demonstrated improvements in cognitive function.

The first stage of the collaboration is intended to test consumer demand and engagement through direct sales to pet owners in Taiwan. The companies said the pilot would inform next steps for broader clinical or veterinary adoption within CHC’s ecosystem. Industry distribution of the original announcement can be found in syndication, including a version carried by Barchart, which reproduced the Business Wire release.

The SoluPet–CHC partnership positions Taiwan as the initial market for this formulation in the Asia region. Company materials cited the pilot as a way to tailor introduction and distribution to Taiwan’s regulatory and clinical environment before any subsequent expansion. SoluPet is identified in the filing as providing manufacturing and scientific guidance to support the pilot and to assist veterinary teams and pet owners in recognizing and managing cognitive-aging symptoms in senior dogs.

CHC’s role, as described, includes overseeing regulatory review, importation, compliance, and distribution within its local networks. The companies framed the pilot as a first phase; future steps described in the announcement would extend access into animal-health settings through CHC’s veterinary network. The announcement emphasized a phased approach to gauge clinical adoption and educational opportunities within those networks.

Where this pilot leads will depend on the results CHC and SoluPet observe in consumer uptake and the regulatory processes CHC manages locally. The announcement itself carries the Dec. 8, 2025 date and the Dec. 9, 2025 @ 3:44 a.m. update timestamp in the timeline supplied with the release.

Source

Original reporting: view the original article.